Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR Gene Amplification”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Ended earlyNCT02706691
What this trial is testing

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Who this might be right for
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene Amplification+7 more
University of Chicago 1
Testing effectiveness (Phase 2)UnknownNCT04096417
What this trial is testing

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene Translocation+16 more
Academic and Community Cancer Research United 14
Testing effectiveness (Phase 2)Looking for participantsNCT07265947
What this trial is testing

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Who this might be right for
Low Grade Upper Tract Urothelial Carcinoma
Tyra Biosciences, Inc 230
Testing effectiveness (Phase 2)Ended earlyNCT02109016
What this trial is testing

Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Who this might be right for
Non-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNSCLC+6 more
Clovis Oncology, Inc. 18
Testing effectiveness (Phase 2)Ended earlyNCT01457846
What this trial is testing

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

Who this might be right for
Gastro-oesophageal Junction CancerGastric Cancer
AstraZeneca 960
Early research (Phase 1)Looking for participantsNCT06915753
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Who this might be right for
Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+11 more
Tyra Biosciences, Inc 100
Testing effectiveness (Phase 2)Study completedNCT01831726
What this trial is testing

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Who this might be right for
Tumor Pathway Activations Inhibited by Dovitinib
Novartis Pharmaceuticals 80
Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Testing effectiveness (Phase 2)Ended earlyNCT04024436
What this trial is testing

TAS-120 in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerFGFR 1 High AmplificationFGFR2 Amplification
Taiho Oncology, Inc. 64
Not applicableEnded earlyNCT05052372
What this trial is testing

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Who this might be right for
Bladder CancerUrothelial CarcinomaTransitional Cell Carcinoma+10 more
xCures 2
Testing effectiveness (Phase 2)UnknownNCT06022289
What this trial is testing

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Who this might be right for
Solid TumorFGF Receptor Gene MutationFGF Amplification+2 more
Tianjin Medical University Second Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01719549
What this trial is testing

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Who this might be right for
Gastric Cancer
Asan Medical Center 19
Testing effectiveness (Phase 2)UnknownNCT05019794
What this trial is testing

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaSolid Tumor
LianBio LLC 80
Testing effectiveness (Phase 2)Ended earlyNCT04189445
What this trial is testing

Futibatinib in Patients With Specific FGFR Aberrations

Who this might be right for
Advanced or Metastatic Solid TumorAdvanced or Metastatic Gastric or Gastroesophageal CancerMyeloid or Lymphoid Neoplasms (MLN)
Taiho Oncology, Inc. 115
Testing effectiveness (Phase 2)Active Not RecruitingNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)Study completedNCT01202591
What this trial is testing

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

Who this might be right for
FGFR Inhibition, Pharmacokinetics, BiomarkersER+ Breast Cancer
AstraZeneca 127